ALGS: Aligos Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
31 institutions reported holding $13.23M of Aligos Therapeutics, Inc. on Form 13F (34 the quarter before). 5 opened a new position and 8 sold out. Shares held by institutions: -17%.
| Largest holders | Shares | Value |
|---|---|---|
| Deep Track Capital, LP | 444,110 | $2.56M |
| Alyeska Investment Group, L.P. | 412,000 | $2.38M |
| Sio Capital Management, LLC | 327,237 | $1.89M |
| MARSHALL WACE, LLP | 246,579 | $1.42M |
| Woodline Partners LP | 177,362 | $1.02M |
| VANGUARD CAPITAL MANAGEMENT LLC | 175,543 | $1.01M |
| BAKER BROS. ADVISORS LP | 83,055 | $479K |
| HHLR ADVISORS, LTD. | 76,247 | $440K |
| D. E. Shaw & Co., Inc. | 66,463 | $383K |
| UBS Group AG | 59,986 | $346K |
Clinical trial readouts
1 Phase 2 or 3 trials by Aligos Therapeutics, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-03 (est.) | ALG-000184 | Chronic Hepatitis B Infection | Phase 2 | 200 | Enrollment complete | NCT06963710 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.